DiaSorin ended 2021 on a healthy note, with impressive demand for non-COVID business. Yet, 2022 guidance was reiterated, with the decline in COVID-19 sales expected to result in an overall sales decline. Nevertheless, it is worth noting that the Luminex acquisition should open up significant opportunities in the US which, along with newer launches and the expansion of existing offerings, should support healthy medium-term results. Moreover, the sell-off in recent months opens up an attractive wi ....
20 Mar 2022
Healthy 2021 performance; 2022 guidance being reiterated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy 2021 performance; 2022 guidance being reiterated
- Published:
20 Mar 2022 -
Author:
Anas PATEL -
Pages:
3
DiaSorin ended 2021 on a healthy note, with impressive demand for non-COVID business. Yet, 2022 guidance was reiterated, with the decline in COVID-19 sales expected to result in an overall sales decline. Nevertheless, it is worth noting that the Luminex acquisition should open up significant opportunities in the US which, along with newer launches and the expansion of existing offerings, should support healthy medium-term results. Moreover, the sell-off in recent months opens up an attractive wi ....